Search Results
Your search for ,NOt matches 22378 pages
Showing 20251 - 20300SABCS 2015: Breast-Conserving Therapy Provided Better Long-Term Outcome Than Mastectomy in Patients With Early-Stage Breast Cancer
Among women with early-stage breast cancer, those who received breast-conserving surgery plus radiation had improved overall survival after 10 years compared with patients who received a mastectomy—76.8% vs 59.7%, respectively—according to a Dutch study by van Maaren et al. After...
SABCS 2015: ESR1 Gene Mutations Are Associated With Worse Overall Survival in Metastatic ER-Positive Breast Cancer
A study by Chandarlapaty et al investigating whether mutations in the estrogen receptor are common in patients with advanced breast cancer and how they affect patient outcomes has found that the D538G and Y537S mutations in the estrogen receptor 1 (ESR1) gene are prevalent in patients with advanced ...
SABCS 2015: Mastectomy Plus Reconstruction Has Higher Complication Rates and Costs Than Lumpectomy Plus Radiation
Among the various guideline-concordant local therapy options available for women with early-stage breast cancer in the United States, mastectomy plus reconstruction had the highest complication rates and complication-related costs for both younger women with private insurance and older women on...
SABCS 2015: Women With Luminal A Breast Cancer Did Not Benefit From Adjuvant Chemotherapy in Phase III Trial
Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates, regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III Dutch Breast Cancer Cooperative Group (DBCG77B) clinical trial...
SABCS 2015: Capecitabine Improved Outcomes for Breast Cancer Patients With Residual Disease After Presurgery Chemotherapy
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer...
SABCS 2015: Denosumab Improves Disease-Free Survival for Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
Adding denosumab (Xgeva) to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor–positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast...
Patient Symptom Surveys Linked to Reduced ER Visits, Improved Survival and Quality of Life
Systematic collection of cancer patients’ symptoms using computer surveys was linked to less frequent emergency room admissions, longer average chemotherapy adherence, greater quality-of-life improvements, and improved survival, according to a new randomized, controlled trial spearheaded by a ...
Improved Overall Survival With Addition of Nanoliposomal Irinotecan to Fluorouracil/Leucovorin in Metastatic Pancreatic Cancer
In the phase III NAPOLI-1 trial reported in The Lancet, Wang-Gillam et al found that the addition of nanoliposomal irinotecan (Onivyde) to fluorouracil (5-FU) and folinic acid (leucovorin) resulted in improved overall survival in patients with metastatic pancreatic ductal cancer who had received...
ASH 2015: Multiple Myeloma Patient Study Shows Promise for Natural Killer Cells
A first-in-human phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient’s own stem cells and high-dose chemotherapy, with little or none of the side effects seen with current treatments. Results from the clinical...
ASH 2015: Updated Results of the Phase I/II GEN503 Study of Daratumumab in Multiple Myeloma
In a study update presented by Plesner et al at the 57th American Society of Hematology (ASH) Annual Meeting, daratumumab (Darzalex) was shown to be safe and effective in combination with lenalidomide (Revlimid) and dexamethasone in patients with relapsed/refractory multiple myeloma (Abstract 507). ...
ASH 2015: Young Adults With Acute Lymphoblastic Leukemia Have Encouraging Survival With Pediatric Chemotherapy Regimen
Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with “adult” treatment protocols, report Dana-Farber Cancer Institute scientists. Overall survival...
ASH 2015: High Response Rates, Long-Term Remissions in Relapsed/Refractory Pediatric ALL, Lymphomas After CTL019 Immunotherapy
Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remissions of over 1 year in 18 patients and over 2 years in nine...
Depressed Head and Neck Cancer Patients 3.5 Times Less Likely to Survive, Have Higher Recurrence Risk
Depression is a significant predictor of 5-year survival and recurrence in head and neck cancer patients, according to a new study from The University of Texas MD Anderson Cancer Center. These findings, published by Shinn et al in Psychosomatic Medicine, represent one of the largest reported...
ASH 2015: Updated Results of Phase III Tourmaline-MM1 Study of Ixazomib in Multiple Myeloma
In a study presented by Moureau et al at the 57th American Society of Hematology (ASH) Annual Meeting, ixazomib (Ninlaro), a recently approved oral proteasome inhibitor, significantly extended progression-free survival for patients with relapsed and/or refractory multiple myeloma (Abstract 727)....
ASH 2015: Children With Acute Lymphoblastic Leukemia Benefit From Prophylactic Antibiotics During Induction Chemotherapy
Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to a study led by investigators from Dana-Farber/Boston Children's...
ASH 2015: Venetoclax Shows Promise for Ultra–High-Risk Chronic Lymphocytic Leukemia With 17p Deletion
In a study to be presented at the 57th American Society of Hematology (ASH) Annual Meeting by Stilgenbauer et al, monotherapy with the investigational agent venetoclax (ABT-199/GDC-0199) induced deep remissions—including complete remission and undetectable minimal residual...
Women’s Health Initiative Clinical Trial Suggests Endogenous Estrogens May Protect Against Colorectal Tumorigenesis in Postmenopausal Women
In a nested case-control study in the Women’s Health Initiative Clinical Trial, reported in Journal of the National Cancer Institute by Murphy et al, endogenous estrogen levels were inversely associated with and sex hormone–binding globulin (SHBG) levels were positively associated with...
Better Invasive Disease–Free Survival With Epirubicin/Cyclophosphamide and Docetaxel vs Epirubicin/Docetaxel and Capecitabine in Breast Cancer
In a Spanish phase III trial (GEICAM/2003-10) reported in the Journal of Clinical Oncology, Martín et al found that invasive disease–free survival was improved with adjuvant epirubicin/cyclophosphamide (EC) followed by docetaxel (EC-T) vs epirubicin/docetaxel followed by capecitabine...
Decreased Prostate-Specific Antigen Screening and Rate of Diagnosis in Early-Stage Prostate Cancer
Recent data indicated that the rates of prostate-specific antigen (PSA) screening and diagnosis of early-stage prostate cancer have decreased since a 2012 U.S. Preventive Services Task Force (USPSTF) statement (released in October 2011) gave a grade D recommendation against PSA screening for all...
ASH 2015: Adding Rituximab to Standard Chemotherapy in CD20-Positive Philadelphia Chromosome–Negative BCP-ALL Improves Event-Free Survival
The results of the randomized Graall-R 2005 study presented by Maury et al at the 57th American Society of Hematology (ASH) Annual Meeting found a new use for rituximab (Rituxan) in acute leukemia (Abstract 1). CD20 is present in 30% to 50% of patients with B-cell precursor acute lymphocytic...
ASH 2015: Test Creates Simulations That May Help Predict Drug Responses, Drive Personalized Treatment
Researchers at the University of Iowa College of Dentistry are partnering with a private company to develop computer simulations that can help personalize cancer care by predicting how a patient will respond to a drug treatment. Their findings were presented by Brogden et al at the 57th American...
ASH 2015: Researchers Identify Children Most at Risk of Overreporting Adherence to At-Home Chemotherapy Regimen
A study presented by Landier et al at the 57th American Society of Hematology (ASH) Annual Meeting examined the common problem of children in remission from acute lymphocytic leukemia (ALL) not adhering to their maintenance drug regimens, thus putting them at risk of relapse (Abstract 82). ...
ASH 2015: Two Studies Focus on Treatment for Cancer-Associated Thrombosis
Two studies presented at the 57th American Society of Hematology (ASH) Annual Meeting examine the common problem of cancer-associated thrombosis. One looked to validate dosing guidelines for avoiding chemotherapy-induced thrombocytopenia, a common autoimmune response to therapy; the second compared ...
ASH 2015: First-in-Human Trial Using Engineered Cells to Target Multiple Myeloma Shows Early Promise
A study (Abstract LBA1) to be reported by Abbas Ali et al at the 57th American Society of Hematology (ASH) Annual Meeting demonstrated promising early outcomes of a first-in-human trial using a patient’s own genetically modified immune cells to eradicate multiple myeloma. The study...
Researchers Use Ovarian Follicles to Preserve Fertility in Preclinical Models
Researchers at the University of Michigan have identified a potential new approach to fertility preservation for young cancer patients that addresses concerns about beginning cancer treatment immediately and the possibility of reintroducing cancer cells during the fertility-preservation process....
Study Shows Abiraterone Acetate Is Useful Even in the Most Aggressive Prostate Cancers
In 1,048 prostate cancer patients previously treated with docetaxel, and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate (Zytiga) led to longer overall disease control, even when a very high Gleason score indicated especially aggressive...
RSNA 2015: Subsolid Lung Nodules Pose Greater Cancer Risk to Women Than Men
Women with a certain type of lung nodule visible on lung cancer screening computed topography (CT) exams face a higher risk of lung cancer than men with similar nodules, according to a new study (SSA04-02) presented by Boiselle et al November 29 at the Annual Meeting of the Radiological Society of...
Study Identifies Ovarian Cancer Cell Hierarchy
Can any cancer cell form another tumor, or is it only select cancer stem cells that give rise to new cancer cells? The answer, a new study finds, is both. Researchers at the University of Michigan Comprehensive Cancer Center looked at human ovarian cancer cells, and found that, for the most part,...
Study Finds Increased Risk of Breast Cancer After False-Positive Screening Mammography
Studies show that an estimated 67% of women aged 40 and older undergo screening mammography every 1 to 2 years. Over the course of 10 screening mammograms, the estimated cumulative probability of at least one false-positive result is 61% for women screened annually and 42% for women screened...
Majority of Men Who Forgo Aggressive Treatment for Prostate Cancer Are Not Monitored Appropriately
An increasing number of men diagnosed with low-risk prostate cancer are opting for active surveillance rather than aggressive treatment to avoid the debilitating potential side effects of surgery and radiation, such as erectile and urinary dysfunction. However, a new study by University of...
RSNA 2015: Study Suggests Breast Density Alone Not a Risk Factor for Cancer
Breast density may not be a strong independent factor for breast cancer risk, according to a new study presented (BR267-SD-THA1) by Katavic et al December 2, 2015, at the Annual Meeting of the Radiological Society of North America (RSNA) in Chicago. Prior research has shown an association between...
Intratumoral Heterogeneity of ALK Fusions and ALK/EGFR Co-alterations in Lung Adenocarcinomas
In a study reported in the Journal of Clinical Oncology, Cai et al found intratumoral genetic heterogeneity of ALK rearrangement and coexisting ALK rearrangement and EGFR mutation in lung adenocarcinomas. Study Details The study involved evaluation for ALK fusions and EGFR mutations in 629...
Prognostic Model for Survival in Advanced-Stage Mycosis Fungoides and Sézary Syndrome
As reported by Scarisbrick et al in the Journal of Clinical Oncology, a Cutaneous Lymphoma International Consortium study in a large population of patients with advanced-stage mycosis fungoides and Sézary syndrome has identified independent prognostic factors for overall survival that can be ...
RSNA 2015: Medicaid Expansion Improves Breast Cancer Screening for Low-Income Women
Low-income women in Medicaid expansion states in the United States are more likely to have a breast screening performed than those in nonexpansion states, according to a study (HP207-SD-MOA2) by Fazeli Dehkordy et al presented November 30, 2015, at the Annual Meeting of the Radiological Society of...
FDA Approves Elotuzumab in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) granted approval for elotuzumab (Empliciti) in combination with two other therapies to treat patients with multiple myeloma who have received one to three prior medications. “We are continuing to learn about the ways the immune system interacts...
Breast MRI After Mammography May Identify Additional Aggressive Cancers
Additional breast cancers found with magnetic resonance imaging (MRI) are sometimes larger and potentially more aggressive than those found on mammography, according to a study published by Iacconi et al in Radiology. Researchers said that in some cases, MRI findings of additional cancers not seen...
Researchers Develop Mathematical Model to Forecast Metastatic Breast Cancer Survival Rates
University of Southern California (USC) researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting, and surfing the Web. For decades, medical schools have taught doctors that...
Elevated C-Reactive Protein May Be Associated With Increased Breast Cancer Risk in Postmenopausal Women Not Using Hormone Therapy
In a study reported in the Journal of the National Cancer Institute, Gunter and colleagues found that increased levels of the inflammatory marker C-reactive protein (CRP) were associated with increased risk of breast cancer in postmenopausal women not using hormone therapy. No associations of...
FDA Approves Single-Agent Nivolumab for Previously Untreated BRAF Wild-Type Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today approved the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Clinical Trial Results The approval is based on data...
FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The U.S. Food and Drug Administration today approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC....
Meta-Analysis Indicates Noninferiority of Overall Survival With Intermittent vs Continuous Androgen-Deprivation Therapy in Prostate Cancer
In a meta-analysis reported in JAMA Oncology, Magnan et al found that intermittent androgen-deprivation therapy was noninferior to continuous androgen-deprivation therapy with respect to overall survival in patients with prostate cancer. Study Details A literature review identified 22 articles...
Citywide Effort Boosts New York City's Colorectal Cancer Screening Rates
A coalition formed by the New York City Department of Health and Mental Hygiene (DOHMH) to increase colorectal cancer screening rates in New York resulted in a 40% increase in screening rates over 4 years. The program may serve as a foundation for other communities to boost cancer screening rates,...
Phase II Study Shows No Benefit of Adding Vismodegib to Gemcitabine in Metastatic Pancreatic Cancer
In a phase II study reported in the Journal of Clinical Oncology, Catenacci et al found no benefit of adding vismodegib (Erivedge) to gemcitabine in patients with metastatic pancreatic cancer. Sonic hedgehog (SHH), an activating ligand of the smoothened receptor (SMO) inhibited by vismodegib, has...
Predicted Burden of Breast Cancer in the United States
In a study reported in Journal of the National Cancer Institute, Rosenberg et al predicted that the number of new invasive plus in situ breast cancers will increase from approximately 283,000 in 2011 to 441,000 in 2030. Modeling suggests that the proportion of estrogen receptor–negative cases ...
Risk of Undetected Cancer in Gynecologic Surgery Higher Than Previously Thought
Minimally invasive gynecologic surgeries have advantages for patients, including shorter hospital stays, quicker recoveries, and less pain. However, power morcellation, a technique that cuts the uterus or fibroid into small pieces in order to extract them from the abdomen through a small incision,...
Chitosane-Based Injectable Biogel Delivers Anticancer Agents Directly Into Tumors in Laboratory Setting
A new, injectable “biogel” is effective in delivering anticancer agents directly into cancerous tumors and killing them, according to a study published by Monette et al in Biomaterials. The technology was developed by researchers at the University of Montreal Hospital Research Centre...
Less Favorable Characteristics for Breast Cancer Diagnosed After Biennial vs Annual Screening in Premenopausal Women
In a study reported in JAMA Oncology, Miglioretti et al found that diagnosis of breast cancer after biennial vs annual mammography screening was associated with a higher risk of less favorable tumor prognostic characteristics among premenopausal women. They also noted a nonsignificantly higher risk ...
FDA Approves Ixazomib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) granted approval for ixazomib (Ninlaro) in combination with two other agents to treat patients with multiple myeloma who have received at least one prior therapy. “As we learn more about the underlying biology of multiple myeloma, we are encouraged ...
Study Advances Potential Test to Distinguish Precancerous Pancreatic Cysts From Harmless Ones
In a retrospective analysis of data from 130 patients with pancreatic cysts, scientists at Johns Hopkins have used gene-based tests and a fixed set of clinical criteria to more accurately distinguish precancerous cysts from those less likely to do harm. The findings may eventually help some...
Patients With Breast Cancer Who Have Prescription Drug Benefits, Higher Incomes More Likely to Start and Continue Hormonal Therapy
A University of Colorado Cancer Center study published by Bradley et al in Breast Cancer Research and Treatment showed that patients with breast cancer whose health insurance plans included prescription drug benefits were 10% more likely to start important hormonal therapy than patients who did not ...
